Catalyst
Slingshot members are tracking this event:
AstraZeneca (AZN) Announces Phase 3 SOLO-2 Results Assessing Lynparza in Treatment-Resistant Ovarian Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 26, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Solo-2, Lynparza, Treatment-resistant, Ovarian Cancer, Platinum-resistant Ovarian Cancer, Brca Mutation-positive
